Depression and Heart Failure With Preserved Ejection Fraction: An Inflammatory Perspective.
4 affiliations
- 1Department of Cardiology The Second Affiliated Hospital of Soochow University Suzhou 215004 Jiangsu China suda.edu.cn.
- 2Suzhou Medical College of Soochow University Suzhou 215123 Jiangsu China suda.edu.cn.
- 3Department of Pathophysiology Chinese Academy of Medical Sciences School of Basic Medicine Institute of Basic Medicine Peking Union Medical College Beijing 100005 China pumc.edu.cn.
- 4Department of Rehabilitation Medicine The Affiliated Suzhou Hospital of Nanjing Medical University Suzhou Municipal Hospital Gusu School Nanjing Medical University Suzhou 215002 Jiangsu China njmu.edu.cn.
Abstract
Depression is a common comorbidity in patients with heart failure with preserved ejection fraction (HFpEF), suggesting potential epidemiological and pathophysiological connections between these two age-related chronic diseases. Extensive clinical evidence demonstrates that depression is closely associated with both the incidence and prognosis of HFpEF. It is currently believed that depression may contribute to the pathogenesis of HFpEF through various interconnected mechanisms, including intestinal dysfunction, endothelial dysfunction, disturbances in fat and energy metabolism, autonomic nervous system dysfunction, hypothalamic-pituitary-adrenal (HPA) axis imbalance, and sex differences. Both conditions often share common comorbidities and genetic predispositions. Notably, inflammation is implicated in all these mechanisms and processes, playing a key role at different stages and facilitating the interaction between the two diseases during their onset and progression. However, the connections between depression and HFpEF have not yet been systematically and thoroughly elucidated. This review aims to comprehensively summarize the associations between depression and HFpEF, focusing particularly on elucidating their interplay in pathogenesis from an inflammation perspective, with special emphasis on the adverse effects of depression on the development of HFpEF. Additionally, we evaluate the management approaches for patients with comorbid depression and HFpEF, which include both pharmacological and nonpharmacological treatments, highlighting that personalized and integrated interventions may offer significant benefits. The review underscores the importance of increased attention and early identification of patients with comorbid depression and HFpEF and is expected to provide valuable insights and guidance for the clinical management of this significant patient population.
Related
- Inflammatory Hematological Indices in Heart Failure with Preserved Ejection Fraction: Associations with Disease Severity and 12-Month Outcomes
- Presumed right atrial myxoma causing mechanical inflow obstruction and a heart-failure-with-preserved-ejection-fraction–mimicking phenotype in a resource-limited setting: A case report
- Neutrophil-to-Lymphocyte Ratio Identifies a Pulmonary Vascular High-Risk Phenotype in Heart Failure with Preserved Ejection Fraction
- EASIX for Long-Term Prognostication in Hospitalized Heart Failure with Preserved Ejection Fraction: Incremental Value Beyond Clinical Risk Markers
- Accelerated pacing rates to improve exercise tolerance, quality of life, and arrhythmia burden in patients with evidence of heart failure with preserved ejection fraction: The PACE-UP rationale and design
BibTeX
@article{chen2026depression,
title = {{Depression and Heart Failure With Preserved Ejection Fraction: An Inflammatory Perspective.}},
author = {Hongfan Chen and Nan Zhang and Yufan Feng and Mengxing Tao and Chi Geng},
journal = {Depression and anxiety},
year = {2026},
month = oct,
doi = {10.1155/da/7169650},
url = {https://europepmc.org/article/MED/42928878},
note = {CC BY},
}
RIS
TY - JOUR
TI - Depression and Heart Failure With Preserved Ejection Fraction: An Inflammatory Perspective.
AU - Hongfan Chen
AU - Nan Zhang
AU - Yufan Feng
AU - Mengxing Tao
AU - Chi Geng
PY - 2026
DA - 2026/10/25
JO - Depression and anxiety
DO - 10.1155/da/7169650
UR - https://europepmc.org/article/MED/42928878
AB - Depression is a common comorbidity in patients with heart failure with preserved ejection fraction (HFpEF), suggesting potential epidemiological and pathophysiological connections between these two age-related chronic diseases. Extensive clinical evidence demonstrates that depression is closely associated with both the incidence and prognosis of HFpEF. It is currently believed that depression may contribute to the pathogenesis of HFpEF through various interconnected mechanisms, including intestinal dysfunction, endothelial dysfunction, disturbances in fat and energy metabolism, autonomic nervous system dysfunction, hypothalamic-pituitary-adrenal (HPA) axis imbalance, and sex differences. Both conditions often share common comorbidities and genetic predispositions. Notably, inflammation is implicated in all these mechanisms and processes, playing a key role at different stages and facilitating the interaction between the two diseases during their onset and progression. However, the connections between depression and HFpEF have not yet been systematically and thoroughly elucidated. This review aims to comprehensively summarize the associations between depression and HFpEF, focusing particularly on elucidating their interplay in pathogenesis from an inflammation perspective, with special emphasis on the adverse effects of depression on the development of HFpEF. Additionally, we evaluate the management approaches for patients with comorbid depression and HFpEF, which include both pharmacological and nonpharmacological treatments, highlighting that personalized and integrated interventions may offer significant benefits. The review underscores the importance of increased attention and early identification of patients with comorbid depression and HFpEF and is expected to provide valuable insights and guidance for the clinical management of this significant patient population.
SN - 1091-4269
SN - 1520-6394
ER -